October 2011- Merck Serono newest R&D hub established in November 2009 in the Beijing area, expanded in 2011 through a strategic partnership with Pharmaron, opening an R&D laboratory on the Pharmaron campus.
The Beijing hub leads drug development for local clinical trials and participation in global clinical trials. Merck Serono's presence enables to liaise more effectively with regulatory officials, academic institutions and other research-oriented organizations as well as conduct clinical trials that accelerate the development of products to treat high-prevalence diseases in China. There is a continuous effort to look for partnerships with local academic institutions and companies.
Research activities at the Beijing R&D hub focus mainly on biomarker research, including pharmacogenomics and bioanalytics, which is part of our stratified medicine approach. The development of Merck serono's activities are centered on Oncology, Neurodegenerative Diseases and Rheumatology. The expertise is concentrated in clinical monitoring, clinical trial management, data management, biostatistics, statistical programming, clinical development units, regulatory affairs, non-clinical development, portfolio and project management, quality assurance, drug safety and medical affairs.
Merck Serono (Beijing) Pharmaceutical R&D Co., Ltd.
The R&D Beijing Hub is an integrated R&D facility, aimed at stimulating innovation, introducing new products to Asia paralleling market timelines in the West, and leading research and development into new treatment solutions for critical diseases in Asia.
CONTACT
Merck Serono (Beijing) Pharmaceutical R&D Co., Ltd.
10F, Tower B, Gemdal Plaza,
No.91 Jianguo Road,
Chaoyang District,
100022 Beijing,
P.R. China
No comments:
Post a Comment